Tenaya Therapeutics, a South San Francisco, CA-based biotechnology company to discover, develop and deliver curative therapies that address the underlying causes of heart disease, secured $106m in Series C funding.
The round was led by RTW Investments, with participation from new investors RA Capital Management, Fidelity Management & Research Company and funds and accounts advised by T. Rowe Price Associates, Inc. and existing investors The Column Group, Casdin Capital, GV and others.
The company intends to use the funds to advance its lead gene therapy program towards clinical studies; progress new programs towards IND-enabling studies; build on existing drug discovery and development capabilities across its three platforms; and invest in cGMP manufacturing capabilities.
Founded by cardiovascular scientists from the Gladstone Institutes and UT Southwestern (UTSW) and led by Faraz Ali, Chief Executive Officer, Tenaya is advancing programs across three therapeutic platforms to address heart disease: Gene Therapy, Cellular Regeneration and Precision Medicine.
FinSMEs
01/03/2021